“Synanthic offers beef producers an excellent choice in the benzimidazole dewormer class,” says Mac Devin, Boehringer Ingelheim Vetmedica Professional Services Veterinarian. “It’s important for producers to have choices in classes of parasite control products to reduce resistance issues.”
There are two classes of anthelmintics available in the marketplace: benzimidazole and macrocyclic lactones.
Devin explains that after several exposures to the same class of anthelmintics, surviving parasite populations begin to develop resistance to the class of anthelmintics. “Having more than one class of anthelmintic to use may become really important for some operations if resistance is becoming an issue,” says Devin. “Synanthic is an important and effective option to have back on the market.”
Synanthic is fast, effective and available in a low-dose formulation. Synanthic is readily absorbed in the gastrointestinal tract and goes to work rapidly to reduce parasite populations. In a study, reported in the Synanthic FOI (Freedom of Information), Synanthic was 100 percent ovicidal within 24 hours.1
Devin adds that Synanthic is labeled for control of Ostertagia ostertagi inhibited L4 larvae at a dosing rate of 4.5 mg/kg. He points out that this is an advantage compared to Safe-Guard® (fenbendazole), which is not effective against L4 larvae or inhibited L4 larvae at its recommended dosage of 5 mg/kg.
Ostertagia ostertagi, otherwise known as brown stomach worm, has been shown to have significant impact on weight gain. A stocker weight gain study showed that non-parasitized animals exhibited 77% greater weight gain than parasitized animals due to appetite suppression caused by O. ostertagi.2
Synanthic is available in two presentations: 22.5% and 9.06%. The 22.5% presentation offers a low-dose option at 1 mL/110 lbs and the 9.06% presentation has a 2.5 mL/110 lbs dosage.
For more information on Synanthic, contact your veterinarian or Boehringer Ingelheim Vetmedica, Inc. representative.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For Boehringer Ingelheim—and its employees—carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
For more information, please visit: www.bi-vetmedica.com. 
